Larimar Therapeutics, Inc. (LRMR)
NGM · Healthcare · Biotechnology
$3.92
+1.82%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$407.2M
Shares Outstanding
103.9M
Exchange
NGM
Currency
USD
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (49.5M) | (64.0M) | (31.1M) | (34.4M) |
| Net Income | (47.7M) | (62.5M) | (29.6M) | (32.8M) |
| Diluted EPS | $-0.61 | $-0.73 | $-0.31 | $-0.30 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (36.5M) | (41.8M) | (90.9M) | (172.5M) |
| Net Income | (35.4M) | (36.9M) | (80.6M) | (165.7M) |
| Diluted EPS | $-1.37 | $-0.84 | $-1.32 | $-2.27 |